Literature DB >> 21504711

Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases.

Bernhard C Danner1, Jan S Gerdes, Klaus Jung, Björn Sander, Christina Enders, Torsten Liersch, Ralf Seipelt, Angelika Gutenberg, Bastian Gunawan, Friedrich A Schöndube, Laszlo Füzesi.   

Abstract

Pulmonary metastases (PM) are frequent in colorectal carcinoma (CRC). However, little is known about the chromosomal imbalances in CRC that accompany metastatic pulmonary disease. We investigated tumor specimens of CRC (n=30) and their corresponding PM by comparative genomic hybridization (CGH). There were no substantial differences in the degree of chromosomal instability between CRC and PM, neither in average number of copy alterations (ANCA; 6.6 ± 0.8 and 7.7 ± 0.9) nor in gains (2.6 ± 0.5 and 2.6 ± 0.4), losses (3.6 ± 0.5 and 4.8 ± 0.6), or amplifications (0.4 ± 0.1 and 0.3 ± 0.1). Basically, similar patterns of chromosomal imbalances could be identified in both CRC and corresponding PM, most frequently including chromosomal gains at 7, 8q, 13q, and 20q, as well as losses at 4, 8p, 18q, and 20p. CRC and corresponding PM differed in frequencies for losses at chromosome arm 5q (3 vs. 26%; P=0.012). Losses at 4q and 11q in CRC were significantly associated with lower 5-year survival rates (80 vs. 24%, P=0.026 and 74 vs. 17%, P=0.007, respectively), and they may represent candidates for adverse prognostic markers in primary CRC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21504711     DOI: 10.1016/j.cancergen.2010.12.003

Source DB:  PubMed          Journal:  Cancer Genet


  9 in total

1.  Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence.

Authors:  Osama E Rahma; Mauricio Burotto; Luisa Matos Do Canto; Alexandre A Germanos; Bassem R Haddad; John L Marshall
Journal:  World J Gastrointest Oncol       Date:  2013-11-15

2.  Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.

Authors:  Dong Wang; Zhong-Zheng Zhu; Hongmei Jiang; Jiayi Zhu; Wen-Ming Cong; Bing-Ji Wen; Song-Qin He; Shu-Fang Liu
Journal:  Hepatol Int       Date:  2015-06-12       Impact factor: 6.047

3.  Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival.

Authors:  Ryan N Ptashkin; Carlos Pagan; Rona Yaeger; Sumit Middha; Jinru Shia; Kevin P O'Rourke; Michael F Berger; Lu Wang; Robert Cimera; Jiajing Wang; David S Klimstra; Leonard Saltz; Marc Ladanyi; Ahmet Zehir; Jaclyn F Hechtman
Journal:  Mol Cancer Res       Date:  2017-02-09       Impact factor: 5.852

4.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

Review 5.  Management of resectable colorectal lung metastases.

Authors:  Sing Yu Moorcraft; George Ladas; Anne Bowcock; Ian Chau
Journal:  Clin Exp Metastasis       Date:  2015-12-10       Impact factor: 5.150

6.  Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.

Authors:  Faik G Uzunoglu; Ebba Dethlefsen; Annkathrin Hanssen; Michaela Wrage; Lena Deutsch; Katharina Harms-Effenberger; Yogesh K Vashist; Matthias Reeh; Guido Sauter; Ronald Simon; Maximillian Bockhorn; Klaus Pantel; Jakob R Izbicki; Harriet Wikman
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

7.  Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes.

Authors:  Hironori Ninomiya; Motohiro Kato; Masashi Sanada; Kengo Takeuchi; Kentaro Inamura; Noriko Motoi; Hiroko Nagano; Kimie Nomura; Yukinori Sakao; Sakae Okumura; Hiroyuki Mano; Seishi Ogawa; Yuichi Ishikawa
Journal:  BMC Cancer       Date:  2013-01-05       Impact factor: 4.430

8.  HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.

Authors:  Feng Xue; Brandon W Higgs; Jiaqi Huang; Chris Morehouse; Wei Zhu; Xin Yao; Philip Brohawn; Zhan Xiao; Yinong Sebastian; Zheng Liu; Yun Xia; Dong Shen; Mike Kuziora; Zhengwei Dong; Hulin Han; Yi Gu; Jianren Gu; Qiang Xia; Yihong Yao
Journal:  J Transl Med       Date:  2015-12-11       Impact factor: 5.531

9.  Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.

Authors:  Sing Y Moorcraft; Thomas Jones; Brian A Walker; George Ladas; Eleftheria Kalaitzaki; Lina Yuan; Ruwaida Begum; Zakaria Eltahir; Andrew Wotherspoon; Angeles Montero-Fernandez; Larissa S Teixeira Mendes; David Gonzalez de Castro; Sanna Hulkki Wilson; Paula Proszek; Ye M To; Eliza Hawkes; Amitesh Roy; David Cunningham; Sheela Rao; David Watkins; Naureen Starling; Anne M Bowcock; Ian Chau
Journal:  Oncotarget       Date:  2017-04-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.